BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34160385)

  • 1. Peripheral blood CD45RO+T cells is a predictor of the effectiveness of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Zhai Z; Wang Z; Jin M; Zhang K
    Medicine (Baltimore); 2021 Jun; 100(25):e26214. PubMed ID: 34160385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.
    Akiyoshi T; Toda S; Tominaga T; Oba K; Tomizawa K; Hanaoka Y; Nagasaki T; Konishi T; Matoba S; Fukunaga Y; Ueno M; Kuroyanagi H
    BJS Open; 2019 Dec; 3(6):822-829. PubMed ID: 31832589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
    Ye W; Shi L; Qian L; Sun Y; Sun X
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
    Lin Y; Lin H; Xu Z; Zhou S; Chi P
    J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
    [No Abstract]   [Full Text] [Related]  

  • 5. The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response.
    Chen CC; Wu ML; Huang KC; Huang IP; Chung YL
    Clin Colorectal Cancer; 2020 Dec; 19(4):e164-e180. PubMed ID: 32387305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
    Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
    BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
    Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
    World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Tominaga T; Akiyoshi T; Yamamoto N; Oba K; Nagasaki T; Yamaguchi T; Konishi T; Fukunaga Y; Ueno M
    Surgery; 2019 Dec; 166(6):1061-1067. PubMed ID: 31345564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Retrospective study of role of neoadjuvant rectal scores in evaluating the 10-year disease-free survival of patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy followed by surgery].
    Zhang WL; Zhou C; Wang WF; Li WH; He JH; Lu ZH; Wu XJ; Lin JZ; Peng JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jun; 27(6):608-614. PubMed ID: 38901994
    [No Abstract]   [Full Text] [Related]  

  • 11. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
    Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
    BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience.
    Li F; Nielsen G; Baran A; Hu J; Wallace D; Preslar M; Fleming F; Temple L; Dunne RF; Noel M; Hezel AF; Tejani MA
    Clin Colorectal Cancer; 2020 Sep; 19(3):e124-e128. PubMed ID: 32409226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited Role for Routine Restaging After Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
    Caturegli I; Molin MD; Laird C; Molitoris JK; Bafford AC
    J Surg Res; 2020 Dec; 256():317-327. PubMed ID: 32712447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy.
    Zhang LN; Xiao W; OuYang PY; You K; Zeng ZF; Ding PR; Pan ZZ; Xu RH; Gao YH
    Tumour Biol; 2015 Sep; 36(10):8213-9. PubMed ID: 25994571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of Restaging Pelvis Magnetic Resonance Imaging After Neoadjuvant Concurrent Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
    Fahmawi Y; Smith C; Grimm L; Khullar S; Rider P; Hunter J; Iliff G; Mneimneh W; Roveda K; Wang B; Prodduturvar P; Alkharabsheh O; McCormick B; Mizrahi M; Khushman M
    Clin Colorectal Cancer; 2020 Dec; 19(4):e281-e287. PubMed ID: 32694005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment Mediators CD8
    Zaghloul H; Abbas A; Abdulah D
    J Gastrointest Cancer; 2021 Mar; 52(1):177-186. PubMed ID: 32112202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer.
    Huang A; Xiao Y; Peng C; Liu T; Lin Z; Yang Q; Zhang T; Liu J; Ma H
    Strahlenther Onkol; 2020 May; 196(5):465-473. PubMed ID: 31828392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
    Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
    Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of CD45RO(+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30 Gy/10f neoadjuvant radiotherapy.
    Wang L; Zhai ZW; Ji DB; Li ZW; Gu J
    Int J Colorectal Dis; 2015 Jun; 30(6):753-60. PubMed ID: 25935450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.